drug screening against yellow fever virus
play

Drug screening against Yellow fever Virus Lucio Freitas Junior - PowerPoint PPT Presentation

Drug screening against Yellow fever Virus Lucio Freitas Junior Departamento de Micorbiologia Instituto de Cincias Biomdicas Universidade de So Paulo The Phenotypic Screening Platform at ICB-USP Chemical and Genetic screening


  1. “Drug screening against Yellow fever Virus” Lucio Freitas Junior Departamento de Micorbiologia Instituto de Ciências Biomédicas Universidade de São Paulo

  2. The Phenotypic Screening Platform at ICB-USP Chemical and Genetic screening Cellular models of disease Chagas disease Leishmaniasis Dengue Yellow Fever Worms Chikungunya Zika Secondary assays for hit MoA and target deconvolution Phenotypic assays

  3. Phenotypic Screening Platform

  4. Screening methodology Reading Fixation and labeling of with DAPI and with Anti-Flavivirus Huh7 cels + ZIKV or YFV antibody + compound 72 h incubation at 37 o C and 5% C0 2 Data analysis

  5. From ideas to Preclinical Candidates DRUG METABOLISM & MEDICINAL CHEMISTRY PHARMACOKINETICS BIOLOGY SCREENING LAB Ensaio Pré-clínico Fase I Hits Lead • Structure- • Eficácia in vivo Activity • PK/PD Relationship • Toxicologia (SAR) • In vitro ADME • Eficácia in vivo • PK/PD • Toxicologia (preliminar) • Target ID

  6. Why is Repurposing import ?

  7. Input Image High Content Screening for Yellow fever YFV

  8. Nuclei Selection YFV

  9. Cytoplasm Selection YFV

  10. Select Population I YFV

  11. Alexa Intensity YFV

  12. Infected cells YFV

  13. FDA for Yellow fever

  14. Screening of a FDA-approved drug library for inhibitors of Y fever virus infection in human cells

  15. Yellow fever assay SOFOSBUVIR 150 1.5 Normalized Activity % 100 1.0 Cell Ratio 50 0.5 0 0.0 -4 -2 0 -50 -0.5 log [Cpd], mg/mL Compound Max activity (%) EC50 (mg/mL) CC50 (mg/mL) S.I. Sofosbuvir 100.07 0.0013 ND 307.665

  16. Yellow fever assay HARVONI 150 1.5 Normalized Activity % 100 1.0 Cell Ratio 50 0.5 0 0.0 -4 -2 0 -50 -0.5 log [Cpd], mg/mL Compound Max activity (%) EC50 (mg/mL) CC50 (mg/mL) S.I. Harvoni 100.07 0.0002 0.1089 659.04

  17. Acknowledgements Phenotypic Screening Platform Carolina Borsoi Moraes Adalberto Araujo-Junior Caio H. Franco Department of Microbiology Luisa Naves Luís Carlos de Souza Ferreira Laura Alcantara Denise Pilger Marcia Mayer Gabriel Padilla Rafaela Bonotto Paolo Zanotto Giovana Cintra Edison Durigon Bruna Wey Joao Renato Rebello luciofreitasjunior@gmail.com Sergio Schenkman

Recommend


More recommend